Home > Neurology > EAN 2020 > Multiple Sclerosis > Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS

Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS

Principal Investigator
Prof. Amit Bar-Or, University of Pennsylvania, PA, USA
EAN 2020
Off-the-shelf ATA188, an allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy, was well tolerated across all 4 dose cohorts in patients with progressive multiple sclerosis (MS) in an open-label phase 1 study. There was a possible signal of therapeutic response, with a higher proportion of patients showing sustained disability improvement with increasing dose [1]. EBV is considered a risk factor in triggering MS. Mounting evidence suggests that EBV-infected immune cells, in particular memory B cells, play an important role in propagating both relapsing and progressive forms of MS. ATA188 offers a novel treatment approach selectively targeting and eliminating EBV-infected B cells and plasma cells in the circulation and central nervous system. A phase 1a multicentre study assessed safety and efficacy of ATA188 in patients with progressive forms of MS. Patients were treated across 4 dose-escalating cohorts, with 6 patients each in cohorts 1...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on